(Versys Clinics)
Earlier this month, I saw an interesting juxtaposition of newly-published papers making headlines. One was about predicting breast cancer recurrence and the effect on chemo choice, the other on predicting premature birth within two months of the due date.
Apples and oranges, perhaps, but both indications use the same technology: gene expression profiling (measuring messenger RNAs, aka transcripts, which guide synthesis of specific proteins). But the studies are at opposite ends of the research trajectory, with the breast cancer paper representing thousands of patients who’ve taken a test that’s been on the market for years, and the prematurity paper a pilot study of only a few dozen women. Read More
Apples and oranges, perhaps, but both indications use the same technology: gene expression profiling (measuring messenger RNAs, aka transcripts, which guide synthesis of specific proteins). But the studies are at opposite ends of the research trajectory, with the breast cancer paper representing thousands of patients who’ve taken a test that’s been on the market for years, and the prematurity paper a pilot study of only a few dozen women. Read More